170 likes | 270 Views
Overview of Health Science Policy Council Activities. May 27, 2006. OBJECTIVES. Describe Health Science Policy Council Discuss Issues and Deposition. OBJECTIVES. Describe Health Science Policy Council. MISSION.
E N D
Overview of Health Science Policy Council Activities May 27, 2006
OBJECTIVES • Describe Health Science Policy Council • Discuss Issues and Deposition
OBJECTIVES • Describe Health Science Policy Council
MISSION To advise the Society on important science, research and policy issues in pharmacoeconomics and outcomes research
Lieven Annemans Jon Clouse Peter Davey Michael Drummond Robert Epstein Jean Paul Gagnon* Bryan Luce Eva Lydick Joel Hay William McGhan Donald Patrick Jim Smeeding Sean Sullivan George Torrance Milton Weinstein Marilyn Dix-Smith ISPOR Scribe - Daniel Klim *Chairman MEMBERSHIP
STRUCTURE • Two weeks before meeting members or others submit new issues to Committee Scribe • Council members identify and freely discuss issues submitted at bi monthly meetings, lead assigned if topic approved • One month after meeting, lead constructs draft brief using approved format • After Council discussion at subsequent meeting second draft constructed • Final approval by Council and referral to Board for discussion and action • If Board approves lead turns brief into Board Action Plan • Held six meetings in 2005/2006
BOARD FORMAT FOR APPROVED ISSUE • Define issue • Describe specific tasks and/or products of action plan • Prioritize the initiatives’ work activities for current year • Provide clarity for operationalizing the work activities, e.g., organization, timelines, and suggested work group members • Suggest management arrangements for the issue, i.e., ideas from council champion on how the intended activity should be managed and monitored • Outline resource requirements, i.e., council champion provides estimates on resources required
OBJECTIVES • Health Science Policy Council • Issues and Deposition
ACTIVITIES • Issues Addressed Approved by the Council and ISPOR Board, and Task Forces Formed: • Continuous Quality Improvement for Cost-Effective Health Care Research and Global Policy • Lead – Bill McGhan • Good Research Practices Task Force on Economic Data Transferability • Lead – Mike Drummond • Drug Cost Good Research Practices • Lead – Jim Smeeding • Approved by Board
ACTIVITIES • Issues Addressed and Approved by the Council and ISPOR Board: • Where does Outcomes Research fit into Evidence-based Health Care Decision-Making? • Bryan Luce • Bridging the Health Measurement Gap? Mission Impossible? • Donald Patrick, George Torrance, Eva Lydick (On Hold) • Probabilistic Analysis in Economic Evaluation • Milt Weinstein • Issue Summary written • Four or Five Authors will draft paper for ViH
ACTIVITIES • Issues Submitted But Have Not Received Final Council Approval • Explaining CEA to Decision-Makers and their Clients • Rob Epstein and Jean Paul Gagnon • How much More Qalys for the Qaly? • Lieven Annemans • Balance between Efficiency and Equity in Health Care Priority Setting • Lieven Annemans • Role of Indirect Costs in CEA • Joel Hay
ACTIVITIES • Issues Submitted But Have Not Received Final Council Approval • How can ISPOR react and support the Required Need for Information Access under MMA • Jim Smeeding • Address three Major Science Policy Efforts: 1) Change Regulatory Approach to Communicating CE Evidence, 2) Partnering Between Industry and Private and Public Payers, and 3) Changing Public Payer to be Encourage and Permit CEA Evidence Submissions • Bryan Luce
ACTIVITIES • Issues Submitted but either sent back to submitter or different judgment rendered: • Four issues last year’s audience reviewed and sent back to submitter with suggestions and comments, e.g., rewrite, join Task Force addressing this issue • Role of Probalistic Microsimulation • Mike Drummond • Handle as two position papers, e.g., Jaime Caro, Pro and David Eddy Con for ViH
NEW ISSUES • Anyone can submit issue to Science Policy Council for development and discussion • Members are open to ideas • Each issue will be discussed and debated • Issue author will be recognized and informed of issue status • Send issues to Jean Paul Gagnon at jean.gagnon@sanofi-aventis.com
FUTURE ACTIVITIES • Role in Policy Development • Identifying new relevant issues • Horizon scanning
Contact InformationJean Paul Gagnonjean.gagnon@aventis.com 800-648-9499 Ext 6379 sanofi-aventis